News & Updates

The interleukin (IL)-23 inhibitor mirikizumab demonstrates superior efficacy in the treatment of patients with moderate-to-severe plaque psoriasis as compared with placebo, with initial responses during induction preserved through the maintenance phase, according to the results of the phase III OASIS-1 trial.

Patients diagnosed with acute myeloid leukaemia with an FLT3 mutation (FLT3+ AML) may benefit from the addition of an FLT3 inhibitor to intensive chemotherapy postinduction by improving event-free (EFS) or overall survival (OS), suggests a study.

Patients with cardiac implantable electronic devices (CIED) see lower levels of physical activity during the COVID-19 pandemic, especially during a period of lockdown, according to a recent Germany study. While younger patients resume exercise with the easing of restrictions, older patients tend to remain inactive.

Women who become pregnant and have a live birth following a diagnosis of breast cancer may have better overall survival (OS) outcomes than those without live births post-cancer, according to a study presented at ESHRE 2022.

Local researchers note a rising trend of late-stage cervical cancer in Singapore, a pattern that they say is likely to be an effect of a less than optimal uptake of screening for the disease.

A newly developed patient decision aid (PDA) aids in the shared decision-making in choosing first-line targeted therapy for metastatic colorectal cancer (CRC), reports a study in Taiwan.